drug safety - Medxy AI

Not All Antidepressants Are the Same: Differential Cardiometabolic and Physiological Effects from a Large Network Meta‑analysis

By MedXY 11/11/2025

A 151‑trial network meta‑analysis of 58,534 participants shows marked differences among 30 antidepressants in weight, blood pressure, heart rate, lipids, glucose and liver enzymes; findings support individualized choice and targeted baseline and follow‑up monitoring.

Clinical Updates news Psychiatry Specialties

Cannabidiol Use and Liver Enzyme Elevations: Insights from a Randomized Clinical Trial in Healthy Adults

By MedXY 09/11/2025

A 4-week randomized trial shows that low-dose cannabidiol (CBD) may cause transient liver enzyme elevations in healthy adults, emphasizing the need for vigilance and further safety assessment of consumer CBD products.

Clinical Updates news OB/GYN & Women's Health Specialties

Evolving Patterns in Antiseizure Drug Use During Pregnancy: Safer Choices and New Uncertainties

By MedXY 07/30/2025

A decade-long French study reveals declining prenatal exposure to high-risk antiseizure drugs, increased use of safer alternatives, and a notable rise in prescriptions for newer drugs with uncertain safety profiles.

Clinical Updates Dermatology Specialties

JAK Inhibitors and Thromboembolic Risk in Atopic Dermatitis: A Comparative Safety Signal

By MedXY 07/29/2025

A large real-world cohort study finds JAK inhibitors increase risk of venous thromboembolism versus dupilumab and methotrexate in atopic dermatitis, highlighting the need for individualized therapy.